PICKERING GRANT 4
4 · Vaxcyte, Inc. · Filed Jun 26, 2026
Research Summary
AI-generated summary of this filing
Vaxcyte CEO Grant Pickering Sells 24,237 Shares (~$1.34M)
What Happened
- Grant Pickering, CEO of Vaxcyte (PCVX), disposed of 24,237 shares on June 26, 2026 in a series of open-market or private sale transactions. The individual lots reported prices between about $53.76 and $56.60 (per-footnote ranges), with per-lot reported proceeds totaling approximately $1,338,270.
- The filings list multiple sale lots (examples: 6,683 shares @ $54.27 for $362,720; 9,137 shares @ $55.27 for $504,956; 6,417 shares @ $56.12 for $360,128), and several smaller lots. These are sales (not purchases) and are generally considered routine disposition activity.
Key Details
- Transaction date: June 26, 2026 (filed the same day).
- Total sold: 24,237 shares for aggregate proceeds ≈ $1,338,270.
- Price details: reported as weighted-average prices by lot; recorded ranges across lots roughly $53.76–$56.60 (see footnotes for per-lot ranges).
- Ownership after transaction: not specified in the summary provided — see the Form 4 for total holdings after the sales.
- Notable footnotes: the sales were effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026 (F1). Some shares are held in trusts for the Reporting Person’s children (F6, F10). Multiple footnotes note that per-lot prices are weighted averages and that the filer will provide full per-price breakdowns upon request.
- Timeliness: filing date matches transaction date (no late filing indicated in provided data).
Context
- These were sales under a Rule 10b5-1 plan, which allows pre-set transactions and is commonly used to avoid trading based on nonpublic information; such sales are typically considered routine and do not, by themselves, indicate management sentiment about the company.
- For investors, purchases by insiders are often viewed as stronger signals than routine planned sales; treat this as a disclosed liquidity event rather than an explicit endorsement or negative view.
Insider Transaction Report
Form 4
Vaxcyte, Inc.PCVX
PICKERING GRANT
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Sale
Common Stock
[F1][F2]2026-06-26$54.27/sh−6,683$362,720→ 468,020 total - Sale
Common Stock
[F1][F3]2026-06-26$55.27/sh−9,137$504,956→ 458,883 total - Sale
Common Stock
[F1][F4]2026-06-26$56.12/sh−6,417$360,128→ 452,466 total - Sale
Common Stock
[F1][F5][F6]2026-06-26$54.34/sh−312$16,956→ 134,903 total(indirect: By Trust) - Sale
Common Stock
[F1][F7][F6]2026-06-26$55.23/sh−356$19,660→ 134,547 total(indirect: By Trust) - Sale
Common Stock
[F1][F8][F6]2026-06-26$55.99/sh−332$18,590→ 134,215 total(indirect: By Trust) - Sale
Common Stock
[F1][F9][F10]2026-06-26$54.22/sh−207$11,224→ 135,008 total(indirect: By Trust) - Sale
Common Stock
[F1][F11][F10]2026-06-26$55.30/sh−602$33,289→ 134,406 total(indirect: By Trust) - Sale
Common Stock
[F1][F12][F10]2026-06-26$56.27/sh−191$10,747→ 134,215 total(indirect: By Trust)
Footnotes (12)
- [F1]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.
- [F10]Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
- [F11]The price reported is a weighted-average price. The shares were sold at prices ranging from $54.80 to $55.72. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F12]The price reported is a weighted-average price. The shares were sold at prices ranging from $56.00 to $56.54. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F2]The price reported is a weighted-average price. The shares were sold at prices ranging from $53.755 to $54.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price reported is a weighted-average price. The shares were sold at prices ranging from $54.755 to $55.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]The price reported is a weighted-average price. The shares were sold at prices ranging from $55.815 to $56.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]The price reported is a weighted-average price. The shares were sold at prices ranging from $53.77 to $54.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Shares are held directly by a trust for the benefit of the Reporting Person's son.
- [F7]The price reported is a weighted-average price. The shares were sold at prices ranging from $54.80 to $55.51. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F8]The price reported is a weighted-average price. The shares were sold at prices ranging from $55.88 to $56.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F9]The price reported is a weighted-average price. The shares were sold at prices ranging from $53.77 to $54.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Signature
Grant Pickering, by /s/ Peter N. Efremenko, Attorney-In-Fact|2026-06-26